EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The HBP Pathway Inhibitor FR054 Enhances Temozolomide Sensitivity in Glioblastoma Cells by Promoting Ferroptosis and Inhibiting O‐ GlcNAcylation

Rongxu Ye, Wanghao Zhang, Huayang Zhang, Shanqiang Qu iD, Junyi Xu iD, Rongyang Xu, Ye Zhu, Guanglong Huang iD, Xi-An Zhang, Guo-Zhong Yi iD

CNS Neuroscience & Therapeutics · 2025

DOI: 10.1111/cns.70546 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2025. Verfasst von Rongxu Ye und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China. Hauptthemen laut MEDLINE: Glioblastoma, Ferroptosis, Temozolomide, Brain Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Guangdong Provincial Department of Science and Technology, Clinical Research Fund of Nanfang Hospital, Southern Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The clinical efficacy of temozolomide (TMZ) in glioblastoma (GBM) patients is often limited by the development of resistance. To date, no clinically validated therapeutic strategies exist to restore sensitivity to TMZ treatment. In this study, we investigated the potential of FR054, a hexosamine biosynthesis pathway (HBP) inhibitor, to sensitize GBM cells to TMZ and elucidated its underlying molecular mechanism.

Methods

TMZ‐resistant U87‐MG and A172 cell lines were generated through stepwise exposure to increasing concentrations of TMZ. Proteomics and bioinformatics analyses revealed HBP activation in these resistant cells. The effects of FR054 alone or in combination with TMZ were assessed using cell line models, GBM organoid models, and intracranial xenograft models. Transcriptomic analysis and validation experiments were further conducted to explore the molecular mechanisms involved.

Results

Long‐term exposure to TMZ induced resistance in U87‐MG and A172 GBM cells, which was associated with the activation of the HBP pathway. PGM3, a key enzyme in the HBP, was found to correlate with poor prognosis in GBM patients. The combination of FR054, a specific PGM3 inhibitor, with TMZ exhibited synergistic inhibitory effects in vitro and superior inhibitory efficacy in GBM organoid models. In vivo, this combination significantly suppressed tumor progression and prolonged survival in orthotopic xenograft mice with minimal side effects. Mechanistically, FR054 enhanced TMZ sensitivity by inhibiting protein O‐GlcNAcylation and promoting ferroptosis via the upregulation of HMOX1 and downregulation of GPX4.

Conclusion

Our findings demonstrate that targeting the HBP pathway with FR054 can overcome TMZ resistance in GBM by reducing O‐GlcNAc modification and inducing ferroptosis. This novel approach enhances the efficacy of TMZ, offering a promising therapeutic strategy for GBM patients with limited treatment options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaFerroptosisTemozolomideBrain NeoplasmsAntineoplastic Agents, AlkylatingHumansAnimalsCell Line, TumorMiceXenograft Model Antitumor AssaysMice, NudeDrug Resistance, NeoplasmFemaleDrug SynergismMale

Stichwörter der Autor:innen

O‐GlcNAcylationferroptosisglioblastomahexosamine biosynthesis pathway inhibitor FR054temozolomide sensitivity

Substanzen

TemozolomideAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
  • The Laboratory for Precision Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
  • The First Clinical Medical College, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
  • School of Public Health, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
  • Nanfang Glioma Center, Guangzhou, Guangdong, People's Republic of China.
  • Institute of Brain Disease, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.

ORCID-Profile: Shanqiang Qu, Junyi Xu, Guanglong Huang, Guo-Zhong Yi

Förderung

  • National Natural Science Foundation of China
  • Guangdong Provincial Department of Science and Technology
  • Clinical Research Fund of Nanfang Hospital, Southern Medical University
  • Research Fund of Nanfang Hospital, Southern Medical University

Zitieren

APA

Ye, R., Zhang, W., Zhang, H., Qu, S., Xu, J., Xu, R., Zhu, Y., Huang, G., Zhang, X. A., & Yi, G. Z. (2025). The HBP Pathway Inhibitor FR054 Enhances Temozolomide Sensitivity in Glioblastoma Cells by Promoting Ferroptosis and Inhibiting O‐ GlcNAcylation. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70546

Vancouver

Ye R, Zhang W, Zhang H, Qu S, Xu J, Xu R, et al. The HBP Pathway Inhibitor FR054 Enhances Temozolomide Sensitivity in Glioblastoma Cells by Promoting Ferroptosis and Inhibiting O‐ GlcNAcylation. CNS Neuroscience & Therapeutics. 2025. doi:10.1111/cns.70546

BibTeX
@article{Ye2025,
  author = {Ye, Rongxu and Zhang, Wanghao and Zhang, Huayang and Qu, Shanqiang and Xu, Junyi and Xu, Rongyang and Zhu, Ye and Huang, Guanglong and Zhang, Xi-An and Yi, Guo-Zhong},
  title = {The HBP Pathway Inhibitor FR054 Enhances Temozolomide Sensitivity in Glioblastoma Cells by Promoting Ferroptosis and Inhibiting O‐ GlcNAcylation},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2025},
  doi = {10.1111/cns.70546}
}
Kostenlos starten →